We are live on ! Find out more
SKYE icon

Skye Bioscience
SKYE

Fund managers haven’t disclosed any holdings of SKYE yet.

SKYE Hedge Fund Activity: Q1 2026 in Review

39 of the 8,133 institutional investors tracked by Wall St. Rank reported a position in Skye Bioscience (SKYE) for Q1 2026, worth a combined $9.91M — down 18% from $12.1M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of SKYE and 5 opened new positions — a net loss of 9 holders — while 8 trimmed existing stakes and 9 added.

The largest buyer was Sphera Funds Management, adding an estimated $163K. The largest seller was Millennium Management, cutting an estimated $99.6K.

  • 39 institutional investors held Skye Bioscience (SKYE) as of Q1 2026, down from 50 in Q4 2025.
  • Funds reported $9.91M of Skye Bioscience stock for Q1 2026, down 18% quarter-over-quarter.
  • 5 funds opened new Skye Bioscience positions in Q1 2026 and 14 closed out, a net change of -9 holders.
  • The largest Skye Bioscience buyer in Q1 2026 was Sphera Funds Management, an estimated $163K added.
  • The largest Skye Bioscience seller in Q1 2026 was Millennium Management, an estimated $99.6K sold.

Based on aggregated 13F filings for Q1 2026.